Efficacy and Safety of Autologous Hematopoietic Stem Cell Transplantation in Treating Type 1 Diabetes Mellitus

    December 2010 in “ Zhonghua neifenmi daixie zazhi ”
    Weiqiong Gu, Shouyue Sun, Jing-shu Wei, Jie Hong, Zhengyi Tang, Jianmin Liu, M Kellis, Weiqing Wang, Guang Ning
    TLDR AHST shows promise for treating type 1 diabetes but needs more research before widespread use.
    The study evaluated the safety and efficacy of autologous nonmyeloablative hematopoietic stem cell transplantation (AHST) in 18 patients with newly-onset type 1 diabetes mellitus. Results showed that 67% of patients became insulin-free, with 44.4% remaining insulin-free at follow-up. Patients experienced significant increases in C-peptide levels, indicating improved islet function. Side effects included gastrointestinal reactions, hair loss, fever, and bone marrow suppression, but no severe organ damage was observed. The study concluded that AHST showed potential benefits and high safety, but recommended caution in its widespread use until further research clarifies the therapeutic mechanism.
    Discuss this study in the Community →